These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23620409)

  • 1. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
    Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K
    Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
    Golding SE; Rosenberg E; Adams BR; Wignarajah S; Beckta JM; O'Connor MJ; Valerie K
    Cell Cycle; 2012 Mar; 11(6):1167-73. PubMed ID: 22370485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
    Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K
    Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
    Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
    Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.
    Vecchio D; Daga A; Carra E; Marubbi D; Baio G; Neumaier CE; Vagge S; Corvò R; Pia Brisigotti M; Louis Ravetti J; Zunino A; Poggi A; Mascelli S; Raso A; Frosina G
    Int J Cancer; 2014 Jul; 135(2):479-91. PubMed ID: 24443327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture.
    Tribius S; Pidel A; Casper D
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):511-23. PubMed ID: 11380241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
    Karlin J; Allen J; Ahmad SF; Hughes G; Sheridan V; Odedra R; Farrington P; Cadogan EB; Riches LC; Garcia-Trinidad A; Thomason AG; Patel B; Vincent J; Lau A; Pike KG; Hunt TA; Sule A; Valerie NCK; Biddlestone-Thorpe L; Kahn J; Beckta JM; Mukhopadhyay N; Barlaam B; Degorce SL; Kettle J; Colclough N; Wilson J; Smith A; Barrett IP; Zheng L; Zhang T; Wang Y; Chen K; Pass M; Durant ST; Valerie K
    Mol Cancer Ther; 2018 Aug; 17(8):1637-1647. PubMed ID: 29769307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019.
    Vecchio D; Daga A; Carra E; Marubbi D; Raso A; Mascelli S; Nozza P; Garrè ML; Pitto F; Ravetti JL; Vagge S; Corvò R; Profumo A; Baio G; Marcello D; Frosina G
    Int J Cancer; 2015 Mar; 136(6):1445-57. PubMed ID: 25091220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells.
    Zhou W; Sun M; Li GH; Wu YZ; Wang Y; Jin F; Zhang YY; Yang L; Wang DL
    Oncol Rep; 2013 Oct; 30(4):1793-801. PubMed ID: 23846672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.
    Carruthers R; Ahmed SU; Strathdee K; Gomez-Roman N; Amoah-Buahin E; Watts C; Chalmers AJ
    Mol Oncol; 2015 Jan; 9(1):192-203. PubMed ID: 25205037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
    Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
    J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study.
    Romano FJ; Guadagno E; Solari D; Borrelli G; Pignatiello S; Cappabianca P; Del Basso De Caro M
    J Cell Biochem; 2018 Jun; 119(6):4867-4877. PubMed ID: 29369420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
    Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
    Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
    Hickson I; Zhao Y; Richardson CJ; Green SJ; Martin NM; Orr AI; Reaper PM; Jackson SP; Curtin NJ; Smith GC
    Cancer Res; 2004 Dec; 64(24):9152-9. PubMed ID: 15604286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo.
    Li Y; Li L; Wu Z; Wang L; Wu Y; Li D; Ma U; Shao J; Yu H; Wang D
    Oncol Rep; 2017 Jul; 38(1):325-335. PubMed ID: 28560406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
    Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
    Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
    Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
    J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
    McCabe N; Hanna C; Walker SM; Gonda D; Li J; Wikstrom K; Savage KI; Butterworth KT; Chen C; Harkin DP; Prise KM; Kennedy RD
    Cancer Res; 2015 Jun; 75(11):2159-65. PubMed ID: 25870146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
    Chalmers AJ; Ruff EM; Martindale C; Lovegrove N; Short SC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1511-9. PubMed ID: 19931733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.